AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Adenosine A2B Receptor Antagonist - Global Pipeline Insight Report 2019 Featuring Adenosine Therapeutics, Almirall, Vernalis, Palobiofarma & CV Therapeutics - ResearchAndMarkets.com

November 4, 2019

DUBLIN--(BUSINESS WIRE)--Nov 4, 2019--

The “Adenosine A2B Receptor Antagonist -Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Adenosine A2B Receptor Antagonist - Pipeline Insight, 2019 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A2B Receptor Antagonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Descriptive coverage of pipeline development activities for Adenosine A2B Receptor Antagonist

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Adenosine A2B Receptor Antagonist

The report assesses the active Adenosine A2B Receptor Antagonist pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the Report

Reasons to Buy

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/a8ohag

View source version on businesswire.com:https://www.businesswire.com/news/home/20191104005751/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 11/04/2019 12:20 PM/DISC: 11/04/2019 12:20 PM

http://www.businesswire.com/news/home/20191104005751/en